BioHarvest Sciences Reports Strong 2025 Performance, $30.8M Capital Raise, and Positive Outlook
Summary
BioHarvest Sciences Inc. issued a year-end shareholder letter highlighting a strong 2025 with an annualized revenue run rate exceeding $36 million, over 60% gross margins, and a significant $30.8 million capital raise, positioning the company for continued growth and near-term adjusted EBITDA breakeven.
Key Events
-
Significant Capital Raise
The company raised approximately $30.8 million in gross proceeds through warrant exercises, debt conversions, and an oversubscribed institutional equity financing, significantly strengthening its balance sheet.
-
Strong Operational Performance
BioHarvest reported an annualized revenue run rate exceeding US$36 million and gross margins above 60% for 2025, its first full year as a NASDAQ-listed company.
-
D2C Product Growth
The VINIA® brand expanded its portfolio with new products like Blood Flow Hydration, reaching over 85,000 active users with more than 90% subscription-based purchases.
-
CDMO Division Milestones
The CDMO Services division secured anchor partnerships and commenced work on two major new plant-based compounds, including a saffron-derived compound where BioHarvest secured 25% ownership.
Analysis
The shareholder letter from CEO Ilan Sobel provides a comprehensive positive update on the company's operational and financial performance. The successful capital raise of approximately $30.8 million, representing a substantial portion of the company's market capitalization, significantly strengthens the balance sheet and provides the necessary capital for planned expansion, including a new 100-ton manufacturing facility. Operationally, the D2C Products business, led by VINIA®, continues aggressive growth with expanding product lines and a growing active customer base, while the CDMO Services division has secured anchor partnerships and commenced work on major new plant-based compounds. The company's stated goal of achieving adjusted EBITDA breakeven in the near term, coupled with being "fully funded," signals improved financial stability and a clear path to profitability, which should instill investor confidence.
At the time of this filing, BHST was trading at $5.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $123.1M. The 52-week trading range was $4.72 to $12.80. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.